How much funding has Cytovale raised?

Cytovale has raised $191.4M in total funding, most recently a Series D round.

Who are Cytovale's investors?

Cytovale's investors include Unknown.

Where is Cytovale headquartered?

Cytovale is headquartered in San Francisco, California, United States.

What industry is Cytovale in?

Cytovale operates in Diagnostics, Healthcare, Medical Devices, Biotech.

Cytovale

We can now see sepsis.

San Francisco, United States · Founded 2013 · $191.4M raised

Headquarters: San Francisco, California
Employees: 51–200
Founded: 2013
Business Model: B2B

Website: cytovale.com
Total Funding: $191.4M
Last Round: $100.0M Series DOct 2024
Rounds: 3

About

Cytovale makes the IntelliSep test, an FDA-cleared in vitro diagnostic that risk-stratifies emergency department patients for sepsis with organ dysfunction by analyzing the biomechanical properties of white blood cells. IntelliSep delivers results in approximately 8 minutes from a small blood sample, enabling faster triage and treatment decisions in a condition where every hour of delay increases mortality by 8%. The test has demonstrated a 42% reduction in mortality and 56% increase in ED discharges in clinical studies.

Summary

Cytovale is a Diagnostics company based in San Francisco, United States, founded in 2013. It has raised $191.4M in total across 3 rounds, most recently a $100.0M Series D round in Oct 2024. Investors include Unknown.

LinkedIn X (Twitter)